| Abstrakt: |
A recent study conducted by researchers from Huazhong University of Science and Technology in Hubei, China, analyzed the safety of pertuzumab, a drug commonly used for the treatment of HER2+ breast cancer. The researchers used the FDA Adverse Event Reporting System (FAERS) to identify potential adverse events associated with pertuzumab. They found that pertuzumab was associated with several adverse events, including hematotoxicity, cardiotoxicity, intestinal perforation, and skin toxicity. The study suggests that healthcare providers should closely monitor patients receiving pertuzumab, particularly within the first month of therapy, and be prepared to take emergency measures, especially for elderly patients and those with cardiovascular diseases. [Extracted from the article] |
